Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19? September 17, 2020 • 9:17 AM EDT
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19 September 15, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia September 3, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences August 27, 2020 • 7:30 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights August 10, 2020 • 8:45 AM EDT
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder August 6, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement August 4, 2020 • 9:00 AM EDT
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference August 4, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference July 30, 2020 • 7:00 AM EDT
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference July 27, 2020 • 7:00 AM EDT
